Medtronic Spine Fights the “Too Big to Fail” Syndrome

article image

With three acquisitions in three years and a reenergized sales team, Medtronic’s Spine business has stopped its multi-year share slide that fed competitors, but maintaining that progress will be tough in an industry that is both mature and fragmented.

2021, while more promising than 2020, is off to a choppy, unpredictable start for medical device companies, with much depending on the trajectory of COVID-19. The healthcare world has improved its ability to handle the pandemic, particularly unpredictable fluctuations in procedure demand, but still businesses are taking a hit. This is certainly true in the spine surgery industry, where companies, while reporting declines in year on year fourth quarter revenues, also are optimistic about a rapid recovery in the US and their own mid- to longer-term outlook.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: